Skip to main content

Marketspace: The immunotherapies markets, 2003–2008

Buy Article:

$44.95 plus tax (Refund Policy)

Analysis of 170 leading and emerging therapeutic antibodies (Ab) and vaccine companies unveils two different business growth trends. The therapeutic antibodies sector will see strong revenue growth with 15 new fully human and humanised product launches and its sales growing from US5bn in 2002 to more than US16bn in 2008. However, the therapeutic vaccines sector, despite its highly innovative nature and newly developed personalised approach, is unlikely to be able to achieve high market penetration with 2008 sales forecast less than US0.5bn.Journal of Commercial Biotechnology (2004) 10, 273–278; doi:10.1057/
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Publication date: 01 March 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more